| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:14 | BioNxt Solutions Inc.: BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments | 200 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery... ► Artikel lesen | |
| 09:35 | BioNxt unterzeichnet Absichtserklärung zum Erwerb von 100% der IP-Rechte und zur gemeinsamen Entwicklung einer sublingualen Arzneimittelformulierung für Chemotherapie- und Immunsuppressionsbehandlungen | 199 | IR-WORLD | Vancouver, BC / ACCESS Newswire / 1. Dezember 2025 / BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT), ein Innovator im Bereich der Bioscience, der sich auf fortschrittliche Systeme... ► Artikel lesen | |
| 08:46 | XFRA MOL0: AUSSETZUNG/SUSPENSION | 188 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMOLECULIN O.N. MOL0... ► Artikel lesen | |
| 08:26 | Faron Pharmaceuticals Ltd: Appointment of CFO | 144 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / December 1, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, announces the appointment... ► Artikel lesen | |
| 09:14 | Alligator Bioscience Announces Publication of REACtiVe-2 Phase 1 trial data in Nature Communications | 137 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 1, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today announced the publication of a peer-reviewed article in Nature communications, reporting... ► Artikel lesen | |
| 10:06 | Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update | 109 | GlobeNewswire (Europe) | All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V:... ► Artikel lesen | |
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON 01.12.2025 | 77 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.12.2025
Aktien
1 IT0005678104 Kaleon S.p.A.
2 IM00BYYPQX37... ► Artikel lesen | |
| 08:00 | Mendus AB: Mendus Announces Large-Scale Vididencel GMP Production Milestone in Manufacturing Alliance with NorthX Biologics | 31 | GlobeNewswire (Europe) | Mendus AB (publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the successful establishment of large-scale GMP production of its lead product... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| AMGEN | 296,45 | 8,22 | +2,77 % | 2,38 | 21.11.2025 | |
| RECORDATI | 51,00 | 1,30 | +2,55 % | 0,63 | 24.11.2025 | |
| GENUS | 29,600 | 0,36 | +1,22 % | 0,22 | 06.11.2025 | |
| BIO-TECHNE | 55,00 | 0,27 | +0,49 % | 0,08 | 17.11.2025 | |
| REGENERON PHARMACEUTICALS | 664,00 | 3,04 | +0,46 % | 0,88 | 20.11.2025 | |
| BRUKER | 42,170 | 0,17 | +0,40 % | 0,05 | 08.12.2025 | |
| BIOGEN | 155,60 | 0,00 | 0,00 % | |||
| ENZO BIOCHEM | 0,388 | 0,00 | 0,00 % | |||
| MYRIAD GENETICS | 6,650 | 0,00 | 0,00 % | |||
| TRANSGENE | 0,970 | 0,00 | 0,00 % |